.png){kind=icon}
.png){kind=icon}
Return
Outcomes of loncastuximab tesirine in heavily pretreated patients with diffuse large B-cell lymphoma, including the post-CAR T-cell therapy setting: A meta-analysis
.png){kind=icon}
PRE
AI
F
H
J
Y
B
J
M
A
M
E
A
A
E
M
L
Y
DOI：10.1002/cncr.70543.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Loncastuximab tesirine, a CD19-directed antibody–drug conjugate, is a therapy for relapsed/refractory diffuse large B-cell lymphoma (DLBCL), including after chimeric antigen receptor T-cell therapy. This study summarized efficacy and safety across published cohorts.
Keywords:
CAR T-cell therapy
diffuse large B-cell lymphoma
loncastuximab tesirine
meta-analysis
relapsed/refractory
Journal
IF:
5.1
Papers:
2.0W
Citations:
6.2W
Organization
Cited Papers